Ameriprise
OREX

Ameriprise’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Ameriprise’s Portfolio OREX Stock Details OREX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-1,327
Closed -$6K – 3957
2016
Q2 		$6K Buy
+1,327
New +$6K ﹤0.01% 3747
2014
Q4 		– Sell
-226
Closed -$9K – 5409
2014
Q3 		$9K Sell
226
-17
-7% -$913 ﹤0.01% 4912
2014
Q2 		$15K Buy
243
+28
+13% +$1.63K ﹤0.01% 4486
2014
Q1 		$14K Buy
215
+50
+30% +$3.38K ﹤0.01% 4390
2013
Q4 		$10K Sell
165
-14,902
-99% -$837K ﹤0.01% 4398
2013
Q3 		$925K Buy
15,067
+217
+1% +$14.7K ﹤0.01% 2710
2013
Q2 		$869K Buy
+14,850
New +$914K ﹤0.01% 2660

Other funds holding OREX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Ameriprise's OREX Position: Q3 2016 in Review

Ameriprise sold out of Orexigen Therapeutics, Inc. (OREX) in Q3 2016, closing a stake of 1,327 shares — an estimated $6K sold.

Ameriprise first reported a position in OREX in Q2 2013 and held it in 7 quarters. The position peaked at $925K in Q3 2013. 55 funds tracked by Wall St. Rank hold OREX as of Q3 2016.

  • Ameriprise reported no remaining Orexigen Therapeutics, Inc. position as of Q3 2016 after selling out during the quarter.
  • Ameriprise sold 1,327 Orexigen Therapeutics, Inc. shares in Q3 2016, an estimated $6K.
  • Ameriprise first reported a position in Orexigen Therapeutics, Inc. in Q2 2013 and held it in 7 quarters.
  • Ameriprise's Orexigen Therapeutics, Inc. position peaked at $925K in Q3 2013.
  • 55 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q3 2016.

Based on Ameriprise's 13F filing for Q3 2016, filed 8 Nov 2016.